Teva Announces FDA Filing Acceptance for AJOVY® (fremanezumab) in Pediatric Episodic Migraine Prevention
Notified -
Globe Newswire7-04-2025, 18:30
VCI Global Completes Founder Group Limited’s IPO on Nasdaq, Records US$5.2 Million in Revenue 24-10-2024, 18:33